Trevi therapeutics, inc. (TRVI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating expenses:
Research and development

22,020

19,339

19,039

17,136

15,047

14,072

0

0

0

General and administrative

8,452

7,306

6,769

5,979

5,031

4,336

0

0

0

Total operating expenses

30,472

26,645

25,808

23,115

20,078

18,408

0

0

0

Loss from operations

-30,472

-26,645

-25,808

-23,115

-20,078

-18,408

0

0

0

Other income (expense):
Change in fair value of Series C redeemable convertible preferred stock liability

-

-

-

-

-

2,105

0

0

0

Change in fair value of obligation for loan success fee

-

-215

-226

-273

-178

-138

0

0

0

Interest income

891

792

613

360

169

156

0

0

0

Interest expense

-

-

-

-

-

174

0

0

0

Total other income (expense), net

728

577

250

-752

-1,321

-2,261

0

0

0

Loss before income tax benefit

-29,744

-26,068

-25,558

-23,867

-21,399

-20,669

0

0

0

Income tax benefit

-23

-18

-63

-83

-103

-124

0

0

0

Net loss

-29,721

-26,050

-25,495

-23,784

-21,296

-20,545

0

0

0

Accretion of redeemable convertible preferred stock

-

-1,535

-1,631

-1,535

-378

-370

0

0

0

Dividends accrued on redeemable convertible preferred stock

-

2,239

3,706

5,068

5,675

5,402

0

0

0

Adjusted net loss attributable to common stockholders

-29,075

-26,754

-27,570

-27,317

-26,593

-25,577

0

0

0

Basic and diluted net loss per common share outstanding

-0.48

12.61

-0.41

-0.63

-13.85

-16.78

-16.22

-13.62

-11.82

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted

17,834

18,092

17,834

10,571

444

438

438

438

434